IRIDEX (IRIX) Stock Forecast, Price & News

0 brokerages have issued 12-month price targets for IRIDEX's shares. Their IRIX share price forecasts range from $2.00 to $2.00. On average, they expect the company's stock price to reach $2.00 in the next twelve months. This suggests that the stock has a possible downside of 9.1%.
View analysts price targets for IRIX or view top-rated stocks among Wall Street analysts.

IRIDEX's stock was trading at $2.01 on January 1st, 2023. Since then, IRIX shares have increased by 9.5% and is now trading at $2.20.
View the best growth stocks for 2023 here.

IRIDEX saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 61,200 shares, an increase of 13.3% from the August 15th total of 54,000 shares. Based on an average daily trading volume, of 29,300 shares, the short-interest ratio is currently 2.1 days. Approximately 0.5% of the shares of the company are short sold.
View IRIDEX's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our IRIX earnings forecast.

IRIDEX Co. (NASDAQ:IRIX) announced its earnings results on Thursday, August, 10th. The medical equipment provider reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by $0.06. The medical equipment provider had revenue of $12.86 million for the quarter, compared to analysts' expectations of $14.23 million. IRIDEX had a negative trailing twelve-month return on equity of 48.09% and a negative net margin of 13.78%.

IRIDEX issued an update on its FY 2023 earnings guidance on Thursday, August, 10th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $55.00 million-$57.00 million, compared to the consensus revenue estimate of $58.05 million.

7 employees have rated IRIDEX Chief Executive Officer Theodore A. Boutacoff on Glassdoor.com. Theodore A. Boutacoff has an approval rating of 64% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other IRIDEX investors own include NVIDIA (NVDA), Trevena (TRVN), CTI BioPharma (CTIC), Agile Therapeutics (AGRX), Genocea Biosciences (GNCA), Idera Pharmaceuticals (IDRA), Lipocine (LPCN), Rigel Pharmaceuticals (RIGL) and SCYNEXIS (SCYX).

IRIDEX trades on the NASDAQ under the ticker symbol "IRIX."

IRIDEX's stock is owned by many different institutional and retail investors. Top institutional investors include Isthmus Partners LLC (2.44%), AMH Equity Ltd (2.07%), Dimensional Fund Advisors LP (1.14%) and Perkins Capital Management Inc. (0.32%). Insiders that own company stock include Nandini Devi and Robert Earle Grove.
View institutional ownership trends.

Shares of IRIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IRIX stock can currently be purchased for approximately $2.20.

IRIDEX (NASDAQ:IRIX) has a market capitalization of $35.71 million and generates $56.97 million in revenue each year. The medical equipment provider earns $-7,550,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis.

The company employs 130 workers across the globe.

IRIDEX's mailing address is 1212 Terra Bella Avenue, Mountain View CA, 94043. The official website for the company is www.iridex.com. The medical equipment provider can be reached via phone at (650) 940-4700, via email at investors@iridex.com, or via fax at 650-940-4710.